REG - Cizzle Biotechnology - Update re. timing of Admission

Cizzle Biotechnology HoldingsAnnouncement

20/12/2022 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221220:nRST3698Ka&default-theme=true

RNS Number : 3698K  Cizzle Biotechnology Holdings PLC  20 December 2022

 

20 December 2022

Cizzle Biotechnology Holdings plc

("Cizzle" or the "Company")

Update re. timing of Admission

Cizzle Biotechnology Holdings plc, the UK based diagnostics developer,
announces that further to the announcement made by the Company on 19 December
2022, the Company has become aware that the next available listing hearing
date for the Admission of the shares pursuant to the Subscription is 4 January
2023. It is now therefore expected that Admission will become effective at
8.00 a.m. on 5 January 2023.

 

Words defined in this announcement shall have the same meaning as in the
announcement released on 19 December 2022.

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited  +44(0) 20 3328 5656
 John Depasquale
 Alex Brearley

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

About Cizzle Biotechnology

Cizzle Biotechnology is also developing a blood test for the early detection
of lung cancer. Cizzle Biotechnology is a spin- out from the University of
York, founded in 2006 around the work of Professor Coverley and colleagues.
Its proof-of-concept prototype test is based on the ability to detect a stable
plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally
occurring cell nuclear protein involved in DNA replication, and the targeted
CIZ1B variant is highly correlated with early-stage lung cancer. For more
information, please see https://cizzlebiotechnology.com You can also follow
the Company through its twitter account @CizzlePlc and on LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDURAVRUOUUUAA